The divestiture includes all of IBAM NA’s cyclotron sites and its research and development facilities. Terms of the transaction were not disclosed. IBA Molecular is jointly owned by SK Capital Partners and Ion Beam Applications S.A.
Commenting on the closing, Renaud Dehareng, CEO of IBA Molecular, said "We are excited to announce the closing of the sale of IBAM NA to IHS. I would like to personally thank all of IBAM NA’s employees for their commitment, dedication and hard work.
The future for IBAM NA is bright under IHS’ ownership given their leadership in nuclear medicine and strong commitment to customers, employees and patients."
Rothschild Inc. served as exclusive financial advisor to IBA Molecular for the transaction.
IBA Molecular is a leading developer, manufacturer and distributor of radiopharmaceutical products and supporting services used in molecular imaging with operations throughout Europe and Asia.
IBA Molecular has a unique product portfolio and pipeline of diagnostic and therapeutic tracers aimed at advancing the development of the global movement towards personalized medicine and making molecular imaging/therapy a major discipline in healthcare.
The company also provides educational, technical and marketing support to medical specialists worldwide to help better respond to patient needs. IBA Molecular is jointly owned by SK Capital Partners and Ion Beam Applications S.A.
Illinois Health and Science (IHS) is a non-profit healthcare system that specializes in enhancing patient care by making strategic investments in healthcare related opportunities. Focused on enhancing the span, experience, and quality of human life, IHS is a science and technology based firm, with specific focus on creating patient value.
Headquartered in Illinois, IHS is led by senior leaders from healthcare and financial services industries.